Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
5.00
Dollar change
+0.07
Percentage change
1.42
%
IndexRUT P/E- EPS (ttm)-0.55 Insider Own11.59% Shs Outstand143.83M Perf Week-2.72%
Market Cap723.10M Forward P/E12.05 EPS next Y0.41 Insider Trans-1.90% Shs Float127.86M Perf Month-16.94%
Income-78.02M PEG- EPS next Q-0.14 Inst Own36.56% Short Float8.33% Perf Quarter-46.35%
Sales175.51M P/S4.12 EPS this Y90.12% Inst Trans8.95% Short Ratio4.43 Perf Half Y-38.80%
Book/sh2.63 P/B1.90 EPS next Y878.13% ROA-15.31% Short Interest10.65M Perf Year-53.79%
Cash/sh2.42 P/C2.06 EPS next 5Y- ROE-19.92% 52W Range4.93 - 12.43 Perf YTD-44.38%
Dividend Est.- P/FCF- EPS past 5Y6.35% ROI-16.96% 52W High-59.77% Beta1.36
Dividend TTM- Quick Ratio4.99 Sales past 5Y3168.98% Gross Margin91.53% 52W Low1.42% ATR (14)0.24
Dividend Ex-Date- Current Ratio5.50 EPS Y/Y TTM28.51% Oper. Margin-47.47% RSI (14)29.85 Volatility3.06% 3.74%
Employees300 Debt/Eq0.26 Sales Y/Y TTM30.95% Profit Margin-44.45% Recom1.75 Target Price10.57
Option/ShortYes / Yes LT Debt/Eq0.22 EPS Q/Q-2.02% Payout- Rel Volume0.60 Prev Close4.93
Sales Surprise0.21% EPS Surprise-16.35% Sales Q/Q58.59% EarningsFeb 15 BMO Avg Volume2.40M Price5.00
SMA20-6.09% SMA50-23.67% SMA200-40.56% Trades Volume1,438,779 Change1.42%
Date Action Analyst Rating Change Price Target Change
Nov-04-22Downgrade Oppenheimer Outperform → Perform
May-05-22Resumed Cantor Fitzgerald Overweight $34 → $25
Dec-10-21Upgrade Oppenheimer Perform → Outperform $33 → $31
Oct-28-21Downgrade Oppenheimer Outperform → Perform $32
Jan-25-21Reiterated H.C. Wainwright Buy $30 → $35
Nov-03-20Reiterated H.C. Wainwright Buy $34 → $28
Jun-17-20Initiated BTIG Research Buy $20
May-05-20Initiated Cowen Outperform
Jan-10-20Initiated Jefferies Buy $27
Dec-16-19Reiterated H.C. Wainwright Buy $25 → $32
Mar-17-24 05:20PM
Feb-29-24 08:30AM
Feb-27-24 08:30AM
Feb-16-24 09:22AM
Feb-15-24 07:25AM
06:49AM Loading…
06:49AM
06:32AM
06:19AM
06:10AM
06:07AM
06:00AM
Feb-08-24 10:00AM
Feb-05-24 08:30AM
Jan-18-24 04:30PM
Jan-05-24 06:00AM
09:40AM Loading…
Dec-28-23 09:40AM
Dec-20-23 06:00AM
Dec-10-23 06:59AM
Nov-23-23 09:55AM
Nov-20-23 09:40AM
Nov-13-23 06:00AM
Nov-07-23 10:30AM
09:55AM
Nov-03-23 09:40AM
08:46AM
Nov-02-23 06:00PM
07:50AM
07:15AM
06:10AM
06:00AM
03:00PM Loading…
Oct-26-23 03:00PM
Oct-19-23 10:31AM
06:00AM
Oct-16-23 09:29AM
Oct-14-23 01:15PM
Oct-13-23 12:00PM
Oct-12-23 12:13PM
Oct-11-23 10:15AM
Oct-09-23 11:10AM
Oct-06-23 09:24AM
Oct-04-23 08:17AM
Oct-03-23 07:43AM
Sep-29-23 09:40AM
Sep-27-23 09:34AM
Sep-26-23 10:56AM
Sep-21-23 06:00AM
Sep-18-23 08:52AM
Sep-06-23 09:55AM
Aug-25-23 09:40AM
Aug-21-23 06:00AM
Aug-03-23 07:15AM
06:11AM
06:00AM
Jul-27-23 07:41AM
Jul-20-23 06:00AM
Jul-19-23 12:05PM
Jul-18-23 10:55AM
Jul-11-23 10:55AM
Jul-03-23 10:42AM
Jul-02-23 05:59PM
Jun-30-23 04:02PM
02:49PM
Jun-29-23 04:05PM
Jun-20-23 09:00AM
Jun-06-23 08:11AM
Jun-01-23 09:00AM
May-26-23 05:16PM
May-23-23 06:56AM
May-17-23 12:14PM
May-11-23 12:00PM
May-09-23 06:02AM
06:00AM
May-04-23 07:15AM
06:11AM
06:00AM
May-03-23 07:51AM
May-02-23 04:36PM
12:00PM
Apr-28-23 06:30AM
Apr-26-23 11:30AM
Apr-25-23 11:00AM
Apr-24-23 05:10PM
06:00AM
Apr-12-23 12:34PM
Apr-11-23 02:41PM
10:26AM
05:39AM
Apr-05-23 06:30AM
Apr-04-23 06:42AM
Apr-03-23 04:00PM
Mar-27-23 04:52AM
Mar-09-23 09:17AM
Mar-08-23 05:09AM
Mar-06-23 04:00PM
Feb-28-23 07:15AM
06:00AM
Feb-24-23 06:00AM
Feb-23-23 07:46AM
Feb-22-23 10:00AM
Feb-21-23 10:00AM
Aurinia Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Victoria, Canada.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Greenleaf PeterChief Executive OfficerMar 06 '24Sale5.60126,981711,0941,522,114Mar 07 04:46 PM
Robertson Stephen P.EVP, General CounselMar 06 '24Sale5.6057,745323,372443,824Mar 07 04:41 PM
Donley Matthew MaxwellEVP, Ops & StrategyMar 06 '24Sale5.5140,665224,064584,072Mar 07 04:43 PM
Miller Joseph MChief Financial OfficerMar 06 '24Sale5.6034,811194,942495,928Mar 07 04:44 PM
Habig Scott MichaelChief Commercial OfficerMar 06 '24Sale5.6017,77799,551474,587Mar 07 04:42 PM
Knappertz VolkerEVP, Research and DevelopmentFeb 27 '24Sale6.104,93030,073319,128Feb 29 04:11 PM
Knappertz VolkerEVP, Research and DevelopmentFeb 20 '24Sale5.4825,146137,800324,058Feb 22 04:35 PM
Habig Scott MichaelChief Commercial OfficerFeb 20 '24Sale5.4815,86786,951492,364Feb 22 04:33 PM
Jayne David R.W.DirectorMay 23 '23Sale11.268,73398,33449,310May 23 05:19 PM
MacKay-Dunn R. HectorDirectorMay 23 '23Sale11.264,81854,25124,225May 23 05:16 PM
Leversage JillDirectorMay 23 '23Sale11.264,81554,21718,528May 23 05:14 PM
Billen DanielDirectorMay 23 '23Sale11.264,65052,35933,393May 23 05:17 PM
Hagan Joseph PDirectorMay 19 '23Sale10.582722,87811,961May 23 05:18 PM